HER-2/neuTOP2A/CSP17基因多色檢測試劑盒

 廣州健侖生物科技?有限公司 

本司長期供應尼古?。商鎸帲z測試劑盒，其主要品牌包括美國NovaBios、廣州健侖、廣州創(chuàng)侖等進口產(chǎn)品，國產(chǎn)產(chǎn)品，試劑盒的實驗方法是膠體金方法。

我司還有很多熒光原位雜交系列檢測試劑盒以及各種FISH基因探針和染色體探針等，。

HER-2/neuTOP2A/CSP17基因多色檢測試劑盒

歡迎咨詢

歡迎咨詢

以下是我司出售的部分FISH產(chǎn)品：

我司還提供：登革熱，黃熱病，基肯孔熱，西尼羅河，立次克體，無形體，蜱蟲，恙蟲，錐蟲，利什曼原蟲，RK39, 漢坦病毒，乙腦，森林腦炎，寨卡病毒 ，H7N9 ,流感，霍亂，軍團菌，結核，諾如病毒，輪狀病毒，炭疽，O157，葡萄球菌 ，流行性出血熱，傷寒桿菌，志賀氏菌檢測試劑,！

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 

【】
【騰訊 】
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室

【企業(yè)文化宣傳】

In the ten major scientific breakthroughs of 2017, the "precise location of gene editing" was listed on the list. For this reason, a famous American consulting company recently released a report that the market size of global genome editors, including CRISPR, TALEN and ZFN, will increase from 3 billion 190 million US dollars in 2017 to 6 billion 280 million US dollars in 2022, with a compound annual growth rate of 14.5%.

The technology of gene editing is commonly known as gene scissors. Whether the prediction of the scissors market cake of American consulting company is accurate or not needs to be tested in the future market. However, from theoretical analysis and prediction, we need to first see the entry threshold of the three gene scissors, including the acceptance of the public, and whether the professional and administrative organs approve.

The main market applications of gene scissors include cell line transformation, genetic engineering, diagnosis and treatment of diseases. At present, the transformation of cell lines is the largest share, and the research of gene editing stem cell therapy is highly recognized.

As far as public and market acceptance is concerned, the lowest threshold for gene scissors and the easiest area to enter is crop improvement, and it is also easily approved. Even if gene scissors are inaccurate, it may cause adverse consequences, but because it is improvement of crops instead of humans, it will not cause direct harm to humans and too many disasters.

Although the market share of gene scissors for disease control is very large, the threshold of market entry is particularly high. The main reason is that the gene scissors need to ensure the safety of the technology and the ethical review and approval of the health management department. As a gene scissors, CRISPR is highly efficient, but its accuracy is doubtful. Therefore, the application of gene scissors has been questioned and opposed by some biomedical experts.

In September 2017, the Oregon Health and Science University's Mitalipov team published a hypertrophic cardiomyopathy caused by CRISPR-Cas9 gene scissors cut off embryos (HCM) of the MYBPC3 gene mutation, called the experimental group in 58 subjects embryos, 42 embryos did not carry pathogenic gene mutation in patients with hypertrophic cardiomyopathy, accounted for more than 74.2%. If the gene is not processed, the normal probability of the fertilized egg is 50% when the 50% spermatozoon is normal. That is to say, the proportion of the compley normal embryos increased from 50% to 74.2% by gene editing, which may eliminate the etiology of hypertrophic cardiomyopathy from the embryo.